📅 Published March 30, 2026 | ♻️ Reviewed August 2, 2026 | 🏷 IVF

PGT-A: Evidence, Limits and Individualized IVF Decisions

Summary:PGT-A assesses embryos for aneuploidy, but it is not a routine requirement for every IVF patient and cannot guarantee a healthy embryo, pregnancy or live birth. Its value must be evaluated by separating outcomes per embryo transfer from cumulative live birth per egg retrieval, then considering age, blastocyst number, prior history, laboratory performance and patient preferences.

What is PGT-A?

PGT-A stands for preimplantation genetic testing for aneuploidy. A laboratory usually biopsies several trophectoderm cells from a blastocyst and reports the sample as euploid, aneuploid, mosaic or inconclusive.

The result describes the sampled cells. It is not an absolute diagnosis of the whole embryo, does not certify that an embryo is “healthy,” and does not replace PGT-M, PGT-SR, prenatal screening or prenatal diagnosis.

ASRM 2024 conclusion:The value of PGT-A as a routine screening test for all IVF patients has not been demonstrated. Use should be discussed case by case with the treating reproductive physician and, where appropriate, a genetics professional.

Two outcome denominators must not be mixed

Outcome	Denominator	How to interpret PGT-A data
Outcome per transfer	Embryos or cycles that reached transfer	The population entering transfer has already been selected, so per-transfer results may look better in some groups. This does not establish benefit for the whole retrieval cycle.
Cumulative live birth per retrieval	All embryos and transfers arising from one egg retrieval	PGT-A does not create embryos. Some embryos may not proceed to transfer because of aneuploid, mosaic or inconclusive results, so the cumulative outcome can differ.

Quoting the performance of transfers using embryos reported as euploid as proof that PGT-A improves overall IVF success mixes denominators. Ask a clinic for age-stratified per-transfer outcomes, cumulative live birth per retrieval, inconclusive-result rates and the proportion of retrievals with no embryo available for transfer.

Process and limitations

Blastocyst development:Embryos are cultured to a stage suitable for biopsy.
Trophectoderm biopsy:A small sample is taken from cells that mainly contribute to the placenta.
Freezing and analysis:The embryo is usually frozen while the sample undergoes chromosome analysis.
Interpretation:The physician and genetics team consider euploid, aneuploid, mosaic or inconclusive reports when planning next steps.

Biopsy is not risk-free:Sampling representation, mosaicism, laboratory procedures and reporting criteria can affect interpretation. Biopsy, freezing and warming also carry technical limitations. Absolute claims that biopsy cannot affect an embryo or that testing necessarily improves success are not supported.

When is an individualized discussion useful?

Age, expected blastocyst number and the likelihood of obtaining an embryo reported as euploid.
Prior pregnancy losses, failed transfers and complete embryology records; these histories do not automatically make PGT-A necessary.
Whether a structural chromosome rearrangement calls for PGT-SR or a monogenic condition calls for PGT-M.
When only a small number of blastocysts is expected, whether the information gained justifies cost, delay and the possibility that no embryo proceeds to transfer.
The laboratory’s biopsy experience, inconclusive-result rate, mosaic-embryo policy and warming outcomes.

Questions to answer before treatment

Define the goal:Is the aim to reduce transfers, obtain genetic information, or improve cumulative live birth per retrieval?
Request like-for-like data:Results should state age, denominator, sample size and reporting period.
Plan for uncertainty:Ask how inconclusive or mosaic results and possible re-biopsy are handled.
Discuss alternatives:These may include transfer without PGT-A, elective single-embryo transfer, PGT-M or PGT-SR when indicated.
Complete informed consent:Consider expected benefit, limitations, cost and personal priorities together.

Evidence source:ASRM, “The use of preimplantation genetic testing for aneuploidy: a committee opinion (2024)”.

Summary: PGT-A is a testing tool, not a success-rate promise

PGT-A may help some families prioritize embryos or avoid selected transfers, but its value depends on the patient group and outcome denominator. It cannot create more embryos, and per-transfer results cannot be substituted for cumulative live birth per retrieval. The final plan should be individualized using complete medical and embryology records.

Sources and editorial notes

Sources in this panel checked: 7 September 2026

The points checked are listed below. Other data and references retain their own dates and scope.

ASRM · PGT-A committee opinion (2024)
The 2024 committee opinion does not establish a benefit from routine PGT-A for every IVF patient. Limitations, embryo numbers and costs require individual discussion.

Compiled by FS Global Ferticare Group. Medical explanations draw on the public guidance listed here; individual test results and treatment arrangements should be discussed with the treating clinical team.

Author and responsibilities · Editorial policy and corrections

Take this question to your next appointment

Write down the purpose before choosing the test.

Record the proposed PGT category and its rationale, and ask about proceeding without it. Provide complete genetic reports instead of paraphrasing a finding.

Ask who interprets inconclusive, mosaic or other uncertain findings and whether further procedures, charges or waiting may follow. PGT-M, PGT-SR and PGT-A address different indications; the IVF guide links to each.

IVF guide Open the preparation checklist

Discuss IVF preparation

📌 Need to know more about PGT-A or other IVF technologies?

← Return to Knowledge Center | Contact us for a free consultation

中文 EN RU